Women receiving cancer treatment in clinical trials exhibited higher risk for severe symptomatic and hematologic adverse events than their male counterparts, according to a study.These findings remained consistent across multiple treatment modalities, including immunotherapy, chemotherapy and targeted therapy, researchers noted.